Pexacerfont

DRUG4 trials

Sponsors

Bristol-Myers Squibb, National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Drug Abuse (NIDA)

Conditions

Alcohol DependenceAlcohol-Related DisordersAlcoholismAnxiety DisorderDaily Oral Pexacerfont for 28 Days (300 mg/Day Loading Dose for 7 Days, FollowedGeneralized Anxiety DisorderMajor Depressive DisorderPlacebo

Early Phase 1

Pexacerfont for Stress-induced Food Craving

TerminatedNCT01656577

National Institute on Drug Abuse (NIDA)Daily Oral Pexacerfont for 28 Days (300 mg/Day Loading Dose for 7 Days, Followed, Placebo

Start: 2012-06-30End: 2015-09-30Updated: 2016-08-18

Phase 1

Study of BMS-562086 in the Treatment of Outpatients With Major Depressive Disorder

CompletedNCT00135421

Bristol-Myers SquibbMajor Depressive Disorder

Start: 2005-11-30End: 2007-10-31Updated: 2010-03-02

Phase 2

Study of Pexacerfont (BMS-562086) in the Treatment of Outpatients With Generalized Anxiety Disorder

CompletedNCT00481325

Bristol-Myers SquibbGeneralized Anxiety Disorder

Start: 2007-07-31End: 2008-03-31Updated: 2015-10-12

Corticotropin-Releasing Hormone Receptor 1 (CRH1) Antagonism in Anxious Alcoholics^

CompletedNCT01227980

National Institute on Alcohol Abuse and Alcoholism (NIAAA)Alcohol Dependence, Alcoholism, Alcohol-Related Disorders +1

Start: 2010-10-31End: 2014-07-31Updated: 2016-02-02

Related Papers

Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder.

2010-05-01123 citations